/images/ppid_59c68470-image-177514764676595268.webp)
What is the story about?
Emcure Pharmaceuticals Ltd has announced a sharp reduction in the starting dose price of its weight management drug Poviztra, aiming to expand patient access across India.
The company has reduced the starting dose price by 55%, with Poviztra (0.25 mg) now priced at ₹3,999 per month, compared to the earlier ₹8,790. On a weekly basis, the revised cost stands at ₹999.
The price revision extends across doses, with an average reduction of 47%, making the therapy more affordable for a wider patient base.
Poviztra is a semaglutide injection administered once weekly through a pen device and is available in multiple strengths, including 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dose of 2.4 mg.
The revised pricing will come into effect from April 3, 2026.
With this move, the company aims to improve accessibility to a widely used and clinically established therapy, particularly at a time when obesity and related health conditions are rising in India.
The drug is based on semaglutide, an established molecule with extensive clinical usage globally, and is designed to support weight management through a structured dosing regimen.
The price cut is expected to bring the treatment within reach of a significantly larger section of patients, aligning with the company’s focus on affordability and broader healthcare access.
Also read: Emcure Pharma Q3 Results: Strong operating performance but stock gives up gains
Emcure Pharma shares closed lower on the NSE at ₹1,552.10, down ₹38.00 or 2.39%.
The company has reduced the starting dose price by 55%, with Poviztra (0.25 mg) now priced at ₹3,999 per month, compared to the earlier ₹8,790. On a weekly basis, the revised cost stands at ₹999.
The price revision extends across doses, with an average reduction of 47%, making the therapy more affordable for a wider patient base.
Poviztra is a semaglutide injection administered once weekly through a pen device and is available in multiple strengths, including 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dose of 2.4 mg.
The revised pricing will come into effect from April 3, 2026.
With this move, the company aims to improve accessibility to a widely used and clinically established therapy, particularly at a time when obesity and related health conditions are rising in India.
The drug is based on semaglutide, an established molecule with extensive clinical usage globally, and is designed to support weight management through a structured dosing regimen.
The price cut is expected to bring the treatment within reach of a significantly larger section of patients, aligning with the company’s focus on affordability and broader healthcare access.
Also read: Emcure Pharma Q3 Results: Strong operating performance but stock gives up gains
Emcure Pharma shares closed lower on the NSE at ₹1,552.10, down ₹38.00 or 2.39%.
